Marinomed Biotech AG (DE:93Z)
FRANKFURT:93Z
Want to see DE:93Z full AI Analyst Report?
93Z Stock Chart & Stats
€20.00
€0.00(0.00%)
At close: 4:00 PM EST
€20.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€11.31 - €21.03
Previous CloseN/A
Volume0.00
Average Volume (3M)13.00
Market Cap
€31.51M
Enterprise ValueN/A
Total Cash (Recent Filing)€911.50K
Total Debt (Recent Filing)€29.09M
Price to Earnings (P/E)2.3
Beta-0.05
Next Earnings
May 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding2,299,925
10 Day Avg. Volume9
30 Day Avg. Volume13
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
93Z FAQ
What was Marinomed Biotech AG’s price range in the past 12 months?
Marinomed Biotech AG lowest stock price was €11.31 and its highest was €21.03 in the past 12 months.
What is Marinomed Biotech AG’s market cap?
Marinomed Biotech AG’s market cap is €31.51M.
When is Marinomed Biotech AG’s upcoming earnings report date?
Marinomed Biotech AG’s upcoming earnings report date is May 26, 2026 which is in 29 days.
How were Marinomed Biotech AG’s earnings last quarter?
Marinomed Biotech AG released its earnings results on Apr 22, 2026. The company reported -€1.463 earnings per share for the quarter, missing the consensus estimate of N/A by -€1.463.
Is Marinomed Biotech AG overvalued?
According to Wall Street analysts Marinomed Biotech AG’s price is currently Overvalued.
Does Marinomed Biotech AG pay dividends?
Marinomed Biotech AG does not currently pay dividends.
What is Marinomed Biotech AG’s EPS estimate?
Marinomed Biotech AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marinomed Biotech AG have?
Marinomed Biotech AG has 2,299,925 shares outstanding.
What happened to Marinomed Biotech AG’s price movement after its last earnings report?
Marinomed Biotech AG reported an EPS of -€1.463 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.985%.
Which hedge fund is a major shareholder of Marinomed Biotech AG?
Currently, no hedge funds are holding shares in DE:93Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marinomed Biotech AG
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.